Product
Autologous MUC1-activated T-cells
Aliases
Autologous MUC1-activated T-lymphocytes
2 clinical trials
15 indications
Indication
Multiple MyelomaIndication
Platinum-Resistant Ovarian CarcinomaIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent fallopian tube carcinosarcomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Ovarian CarcinosarcomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Primary Peritoneal CarcinosarcomaIndication
Fallopian Tube CarcinomaIndication
Ovarian CancerIndication
Primary Peritoneal CarcinomaClinical trial
Use of Natural Signals and Ambient Dendritic Cells to Culture-Expand Cancer Targeting T-Cells Directly From Unfractionated Peripheral Blood: A Phase 1 T-Cell Dose Escalation Trial Targeting Relapsed and Refractory MUC1-Expressing Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Phase 1 Clinical Trial Using Autologous, MUC1-Activated T Cells Expanded From Peripheral Blood in Patients With Relapsed and Resistant Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2028-09-01